Research advances of anti-CD40 monoclonal antibody.
10.7534/j.issn.1009-2137.2013.02.053
- Author:
Long-Long LUO
1
;
Yan ZHANG
;
Chun-Mei HOU
;
Chun-Xia QIAO
;
Yan LI
Author Information
1. Academy of Military Medical Sciences, Beijing, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Antibodies, Monoclonal;
CD40 Antigens;
immunology;
Humans;
Neoplasms
- From:
Journal of Experimental Hematology
2013;21(2):508-512
- CountryChina
- Language:Chinese
-
Abstract:
CD40 and its receptor CD40L are a very important pair of co-stimulating molecule in immune response, which have extensive biological effects. After stimulating CD40 signal, it can exert corresponding function through MAPK (JNK, ERK, p38) pathway, PI3K cascade, as well as NF-κB and STAT. The CD40 signal is closely related to tumor immunity, this moleculer has already become targeted-molecule for cancer treatment. Recently, there have been many anti-CD40 monoclonal antibodies displaying good anti-cancer effect, among which CHIR-12.12, SGN-40 and CP-870, 893 developed rapidly and successively have entered clinical research stage. This review focuses the status of anti-CD40 monoclonal antibody, including distribution of CD40, physiological function of CD40, CD40 and tumor immunity, anti-CD40 monoclonal antibodies and so on.
